Abstract

Pulmonary air leaks are medical complications of thoracic surgery for which fibrin sealant is the main treatment. In this study, innovative sealants based on hydrophobically modified Alaska pollock-derived gelatin (hm-ApGltn) and a poly(ethylene)glycol-based 4-armed cross-linker (4S-PEG) have been developed and their burst strengths have been evaluated using fresh rat lung. The developed sealants show higher lung burst strength compared with the nonmodified original ApGltn (Org-ApGltn)-based sealant and a commercial fibrin sealant. The maximum burst strength of the hm-ApGltn-based sealant is 1.6-fold higher than the Org-ApGltn-based sealant (n = 5, p < 0.05), and 2.1-fold higher than the commercial fibrin sealant (n = 5, p < 0.05). Cell culture experiments show that modification of ApGltn with cholesteryl or stearoyl groups effectively enhances anchoring to the cell surface. In addition, binding constants between hm-ApGltn and extracellular matrix proteins such as fibronectin and fibrillin are increased. Therefore, the new hm-ApGltn/4S-PEG-based sealant has the potential for applications in thoracic surgery.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call